Allopathic Spinraza Nusinersen 12mg Injection, 1ml-5ml, Intravenous

The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy(SMA), a rare and often fatal genetic disease affecting muscle strength and movement.Biogen, which is licensing Spinraza from Ionis Pharmaceuticals, said this week that one dose will have a list price of $125,000. That means the drug will cost $625,000to $750,000 to cover the five or six doses needed in the first year, and about$375,000 annually after that, to cover the necessary three doses a year